BioMarin Pharmaceutical Inc.

BMRN13 Dec 2024
Healthcare
$65.62
+0.00 (+0.44%)
Lowest Today
$65.42
Highest Today
$66.68
Today’s Open
$65.62
Prev. Close
$65.97
52 Week High
$99.56
52 Week Low
$61.15
To Invest in BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

Healthcare
BMRN13 Dec 2024
+0.00 (+0.44%)
1M
3M
6M
1Y
5Y
Low
$65.42
Day’s Range
High
$66.68
65.42
52 Week Low
$61.15
52-Week Range
52 Week High
$99.56
61.15
1 Day
-
1 Week
-0.27%
1 month return
-0.22%
3 month return
-21.78%
6 month return
-22.02%
1 Year return
-31.21%
3 Years return
-21.26%
5 Years return
-18.45%
10 Years return
-
Institutional Holdings
BlackRock Inc
11.93
Vanguard Group Inc
10.12
PRIMECAP Management Company
9.9
Dodge & Cox
7.29
Capital Research Global Investors
5.51
Viking Global Investors LP
5.12
Dodge & Cox Stock I
4.68

Market Status

Fundamentals
Market Cap
12732.84 mln
PB Ratio
2.35
PE Ratio
40.02
Enterprise Value
12405.09 mln
Total Assets
6841.6 mln
Volume

Company Financials

Fund house & investment objective

Company Information
BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Organisation
BioMarin Pharmaceutical Inc.
Employees
3401
Industry
Biotechnology
CEO
Mr. Alexander  Hardy
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities